Showing 2361-2370 of 5644 results for "".
- Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conferencehttps://modernod.com/news/clearside-biomedicals-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exudation-and-degeneration-2022-virtual-conference/2480642/Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12,
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Global Eye Health Body Unites With Novartis to Strengthen Eye Health in Africahttps://modernod.com/news/global-eye-health-body-unites-with-novartis-to-strengthen-eye-health-in-africa/2480626/The International Agency for the Prevention of Blindness (IAPB) has joined together with Novartis in a partnership to strengthen eye health in Sub-Saharan Africa. The new 3-year relationship will support effective policy dialogue, planning, and implementation of eye health services in the re
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- Johns Hopkins: Study Finds Up to 30% of Patients with Wet Macular Degeneration May Safely Stop Eye Injectionshttps://modernod.com/news/johns-hopkins-study-finds-up-to-30-of-patients-with-wet-macular-degeneration-may-safely-stop-eye-injections/2480583/In a preliminary study of 106 people with wet age-related macular degeneration (AMD), Johns Hopkins Medicine researchers report that as many as a third of those with the blinding retinal disease may someday be able to safely stop eye injection therapy without further vision loss. The fi
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- AffaMed Therapeutics, licensee of Dextenza in Certain Asian Markets, Doses Their First Patient in Clinical Trial in Cataract Surgery Patientshttps://modernod.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surger